JPMorgan downgrades Centrica stock rating to neutral on limited upside

JPMorgan has downgraded Centrica Plc. to Neutral from Overweight, reducing its price target to GBP1.67 from GBP1.70, citing a balanced risk/reward profile after the stock's substantial 290% outperformance since Q3 2020. The bank believes much of the previously identified value from balance sheet strength and restructuring has been realized, alongside normalizing commodity prices and increased energy market volatility. JPMorgan's 2025 and 2026 EPS estimates are now 11% and 5% below Bloomberg consensus, respectively, with the new price target implying only 2% upside potential, while upcoming interim results on July 24 are expected to confirm challenging, though one-off, conditions in key energy markets.

Analysis

JPMorgan has recalibrated its stance on Centrica Plc. to Neutral from Overweight, signaling that the stock's pronounced outperformance has largely exhausted near-term upside potential. The downgrade is underpinned by the stock's 290% appreciation since Q3 2020, a period during which the bank's initial bullish thesis—centered on an underappreciated balance sheet and restructuring benefits—has materialized. The current environment of normalizing commodity prices and reduced energy market volatility further supports a more balanced risk/reward outlook. Critically, JPMorgan's forward-looking earnings per share estimates for 2025 and 2026 are now 11% and 5% below Bloomberg consensus, respectively, suggesting earnings risk. The revised price target of GBP1.67 implies a marginal 2% upside from current levels. While the upcoming interim results on July 24 are anticipated to confirm difficult conditions in key segments, the bank frames these challenges as likely one-off events, rather than a structural deterioration.

Key Decisions for Investors

• Investors who have benefited from the significant outperformance since 2020 should consider trimming positions, as the primary drivers of the previous 'overweight' rating appear to be fully priced in.
• Potential new investors should exercise caution, as JPMorgan's below-consensus EPS forecasts for 2025-2026 and the minimal price target upside suggest a heightened risk of negative earnings revisions.
• Monitor the July 24 interim results closely for confirmation of the expected market challenges and, more importantly, for management's commentary on whether these headwinds are truly temporary.